Pluri (NASDAQ:PLUR) Releases Quarterly Earnings Results

Pluri (NASDAQ:PLUR) released its earnings results on Wednesday. The company reported ($0.65) EPS for the quarter, Zacks reports. Pluri had a negative return on equity of 4,191.91% and a negative net margin of 1,701.19%.

Pluri Trading Up 7.5%

PLUR stock traded up $0.31 during mid-day trading on Wednesday, hitting $4.45. 46,161 shares of the company were exchanged, compared to its average volume of 19,789. Pluri has a 12-month low of $3.22 and a 12-month high of $7.13. The firm has a market capitalization of $36.29 million, a P/E ratio of -0.86 and a beta of 0.63. The business has a fifty day simple moving average of $4.34 and a 200-day simple moving average of $4.73. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 51.65.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pluri in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $12.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC bought a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri as of its most recent SEC filing. 16.59% of the stock is currently owned by institutional investors and hedge funds.

About Pluri

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.